ClinicalTrials.gg
RecruitingNCT07530094STELLAR01Updated Apr 15, 2026

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Camrelizumab in Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, sponsored by Ning Jiang, M.D./Ph.D.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Ning Jiang, M.D./Ph.D. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2025, registered Apr 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing camrelizumab in Esophageal Neoplasms — 5 open to participants now, 6 under way, none of them phase 3. camrelizumab · Esophageal Neoplasms.

Planned enrollment
7th of 17
98 · median 63
Started
2025
with 1 other
Phase 2
10 of 17
5 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Ning Jiang, M.D./Ph.D.

Among the 17 studies testing camrelizumab in Esophageal Neoplasms, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 10 in phase 2, and was the 17th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

5 of the 17 studies testing camrelizumab in Esophageal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.

Read the detailed description

The RTOG 8501 trial established definitive chemoradiotherapy (dCRT) as the standard treatment for patients with locally advanced unresectable esophageal cancer. Although long-term survival and even cure have been observed in a subset of patients treated with dCRT, the overall short- and long-term outcomes remain unsatisfactory. For example, the complete response (CR) rate after dCRT is only approximately 25%, most patients eventually experience local recurrence or distant metastasis, and the 5-year overall survival rate is only about 20%. Therefore, there remains a substantial unmet medical need for improving the treatment of patients with locally advanced unresectable esophageal cancer.In patients with unresectable esophageal cancer, several small-sample exploratory studies have investigated the combination of immunotherapy with dCRT. The EC-CRT-001 study preliminarily demonstrated that dCRT combined with toripalimab achieved a CR rate of 62% and a 1-year overall survival rate of 78.4% in patients with locally advanced unresectable esophageal squamous cell carcinoma. A study by Zhao et al. explored induction chemo-immunotherapy followed by concurrent chemoradiotherapy, reporting a 1-year overall survival rate of 88.0% and a 2-year local control rate of 81.7%, which were also superior to those reported in traditional studies of chemoradiotherapy alone. Taken together, these findings suggest that the incorporation of immune checkpoint inhibitors (ICIs) into definitive chemoradiotherapy-based multimodal treatment may improve outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma.Currently, several large randomized controlled trials, such as RATIONALE 311 and KUNLUN, are ongoing to evaluate the efficacy of immunotherapy maintenance following concurrent chemoradiotherapy compared with placebo. However, the optimal integration strategy of chemoradiotherapy and immunotherapy remains unclear. In lung cancer, the PACIFIC trial established the cornerstone role of immunotherapy maintenance in patients with unresectable stage III disease. In esophageal cancer, other studies such as SKYSCRAPER-07 are also investigating the efficacy and safety of immunotherapy maintenance following definitive chemoradiotherapy. Nevertheless, which combination strategy of conventional chemoradiotherapy and ICIs can best balance efficacy and toxicity remains to be elucidated and warrants further clinical investigation.Based on this background, the present study aims to investigate and compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in patients with locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.

03

Conditions studied

  • Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal carcinoma
  • Definitive Chemoradiotherapy
  • immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient or their legal representative is able to sign the written form and understands and agrees to comply with the study requirements;
  2. Age ≥ 18 years and \< 75 years at the time of signing the informed consent form, regardless of gender;
  3. confirmed esophageal squamous cell carcinoma, confirmed by imaging examinations such as CT, MRI, or PET-CT as locally advanced unresectable ESCC (medically unsuitable for surgery or refusal of surgical intervention), and suitable for cCRT, including: stages II-IVa and certain cases of stage IVb (involving only supraclavicular lymph node ) (AJCC version 8 ) meeting the criteria;
  4. Estimated of at least 6 months;
  5. performance status score of 0-2;
  6. Presence of measurable and/or non- as defined by the (RECIST 1.1);
  7. No prior systemic anti-tumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy, local therapy, or other treatments);
  8. Adequate organ function, as indicated by laboratory test results obtained within 14 days prior to enrollment:
  9. a. Achieved without the need for blood transfusion, growth factor therapy, or other supportive medications that significantly affect , count, or within ≤ 14 days before sample collection during screening: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L;
  10. b. Estimated ≥ 60 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration equation (Appendix 9);
  11. c. Serum total ≤ 1.5 × (for patients with Gilbert's syndrome, total bilirubin must be ≤ 3 × ULN);
  12. d. and ALT \< 3 × ULN;
  13. For patients with inactive/asymptomatic carriers, chronic or active infection, the following criteria must be met:
  14. HBV DNA \< 500 IU/mL (or 2500 copies/mL) during screening;
  15. Note: Patients with positive hepatitis B surface antigen or detectable HBV DNA should be managed according to treatment guidelines. Patients receiving antiviral therapy during screening must have undergone treatment for > 2 weeks prior to enrollment;
  16. Female patients of must voluntarily agree to use highly effective during the study period, for ≥ 120 days after the last dose of camrelizumab or placebo, and for ≥ 180 days after the last dose of chemoradiotherapy, and must have a negative urine or serum pregnancy test result within ≤ 7 days prior to enrollment;
  17. Male patients who are not sterilized must voluntarily agree to use highly effective contraception during the study period, for ≥ 120 days after the last dose of camrelizumab or placebo, and for ≥ 180 days after the last dose of chemoradiotherapy.

Exclusion criteria

Exclusion Criteria:

Here is the translation of the exclusion criteria into English:

  1. History of other ;
  2. History of fistula caused by primary tumor infiltration;
  3. Patients at high risk of esophageal fistula or with signs of esophageal perforation;
  4. History of esophageal cancer surgery;
  5. Poor nutritional status, with less than 18.5 kg/m², or PG-SGA score ≥ 9;
  6. Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or medical intervention (within 2 weeks prior to randomization);
  7. Known intolerance or resistance to the chemotherapy regimen specified in the study protocol;
  8. Prior receipt of any other anti-tumor therapy for ESCC (e.g., therapies targeting , PD-L1, PD-L2, or other tumor immunotherapies, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor treatments);
  9. Patients with active disease or a history of autoimmune disease that may relapse;
  10. Note: Patients with the following conditions are not excluded and may proceed to further screening:

a. Controlled type I diabetes; b. Hypothyroidism (controlled with hormone replacement therapy only); c. Controlled celiac disease; d. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia); e. Any other disease that is not expected to relapse in the absence of external triggers; k. Presence of other active malignancies within ≤ 2 years prior to enrollment, except for the specific cancer under study in this trial and locally recurrent cancers that have been cured (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast); l. Any condition requiring systemic treatment with (dose > 10 mg/day of prednisone or equivalent) or other agents within ≤ 14 days prior to randomization;

Note: Patients who have currently or previously used any of the following steroid regimens are not excluded:

a. Adrenal replacement steroids (prednisone ≤ 10 mg/day or equivalent); b. Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; c. Short-term (≤ 7 days) prophylactic use of corticosteroids (e.g., for prevention of contrast agent allergy) or for treatment of non-autoimmune conditions (e.g., delayed reaction caused by contact allergens); m. Presence of uncontrolled diabetes, laboratory test abnormalities for potassium or sodium > Grade 1 despite standard medical therapy, or hypoalbuminemia ≥ Grade 3 within ≤ 14 days prior to enrollment; n. History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases including pulmonary fibrosis, acute lung diseases, etc.; o. Presence of severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy (including tuberculosis infection, etc.) within 14 days prior to enrollment; Note: Patients with chronic or infection are permitted to receive antiviral therapy; p. Known history of infection; q. Major surgery performed within ≤ 28 days prior to enrollment; Note: Minimally invasive procedures (e.g., peripherally inserted central catheter [PICC]) are not considered major surgery; r. Prior stem cell transplantation or organ transplantation; s. Presence of any of the following cardiovascular risk factors:

  1. Cardiac chest pain occurring within ≤ 28 days prior to randomization, defined as moderate pain limiting instrumental activities of daily living;
  2. Symptomatic pulmonary embolism occurring within ≤ 28 days prior to randomization;
  3. Acute myocardial infarction occurring within ≤ 6 months prior to randomization;
  4. History of heart failure reaching (NYHA) Class III or IV within ≤ 6 months prior to randomization;
  5. Ventricular arrhythmia ≥ Grade 2 occurring within ≤ 6 months prior to randomization;
  6. Cerebrovascular accident occurring within ≤ 6 months prior to randomization;
  7. Uncontrolled hypertension despite antihypertensive medication, i.e., systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, within ≤ 28 days prior to randomization;
  8. Syncope or seizure occurring within ≤ 28 days prior to randomization;

t. History of severe hypersensitivity reaction to other monoclonal antibodies or to cisplatin or paclitaxel; u. Receipt of any chemotherapy, immunotherapy (e.g., interleukins, interferons, thymosins, etc.), or any treatment within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug; v. Use of herbal medicines for cancer control within 14 days prior to the first dose of study drug; w. Patients with toxicities from prior anti-tumor therapy that have not recovered to baseline or stable levels, unless considered as adverse events without safety risks (e.g., alopecia, neuropathy, specific laboratory abnormalities); x. Receipt of within ≤ 28 days prior to randomization; Note: Seasonal influenza vaccines are typically inactivated vaccines and are permitted. Intranasal vaccines are live vaccines and are not permitted; y. Presence of underlying diseases (including laboratory abnormalities), alcohol or substance abuse or dependence that may interfere with study drug administration, affect interpretation of drug toxicity or adverse events, or compromise the patient's compliance with study procedures; z. Concurrent participation in another therapeutic clinical trial; aa. Other factors that, in the investigator's judgment, may necessitate premature termination of the study participation (e.g., prisoners or individuals under involuntary detention; individuals detained involuntarily for treatment of psychiatric or physical illnesses such as infectious diseases).

Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy

    Nab-paclitaxel plus carboplatin will be administered every 3 weeks as one cycle, for a total of two cycles, concurrently with camrelizumab immunotherapy and radiotherapy (45 Gy in 18 fractions, 5 days per week, D3-D26). After completion of concurrent chemoradiotherapy plus immunotherapy, the decision to add two cycles of adjuvant chemotherapy will be made based on a comprehensive assessment of the patient's physical condition and other relevant factors. Patients will receive camrelizumab as maintenance therapy every 3 weeks for up to 12 months (a total of 17 cycles), or until disease progression, unacceptable toxicity, investigator decision, or withdrawal of consent by the patient.

    Biological: Camrelizumab

  • Experimental
    short-course definitive chemoradiotherapy plus immunotherapy maintenance

    Nab-paclitaxel plus carboplatin will be administered every 3 weeks as one cycle, for a total of two cycles, concurrently with radiotherapy (45 Gy in 18 fractions, 5 days per week, D3-D26). After completion of concurrent chemoradiotherapy, the decision to add two cycles of adjuvant chemotherapy will be made based on an overall assessment of the patient's physical condition and other relevant factors. Patients will receive camrelizumab as maintenance therapy every 3 weeks for up to 12 months (a total of 17 cycles), or until disease progression, unacceptable toxicity, investigator decision, or withdrawal of consent by the patient.

    Biological: Camrelizumab

Interventions

  • BiologicalCamrelizumab

    This study aims to compare the efficacy and safety of two novel treatment strategies-short-course definitive chemoradiotherapy combined with adjuvant camrelizumab, and short-course definitive chemoradiotherapy combined with concurrent plus adjuvant camrelizumab-in patients with locally advanced unresectable esophageal squamous cell carcinoma.

    Also known as: nab-paclitaxel + carboplatin, short-course definitive radiotherapy

06

What researchers measure

Primary outcomes

  1. 1-year Progression- Free Survival

    1-year progression-free survival (PFS) defined as the probability from study enrollment to tumor progression (in any aspect) or death from any cause within 1 year.

    Time frame: from study enrollment to tumor progression (in any aspect) or death from any cause within 1 year.

Secondary outcomes

  1. complete response rate

    Complete response rate at 3 months after completion of radiotherapy: assessed by CT, high-resolution MRI and/or PET-CT, in combination with endoscopic ultrasound-guided bite-on-bite biopsy.

    Time frame: 3 months after completion of radiotherapy

  2. treatment-related adverse events

    Grade ≥3 treatment-related adverse events will be recorded according to CTCAE version 5.0 during the treatment period, from study enrollment until 90 days after the final administration of chemoradiotherapy.

    Time frame: from study enrollment until 90 days after the final administration of chemoradiotherapy

  3. Overall Survival

    Defined as from date of enrollment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months

    Time frame: From study enrollment to death from any cause, assessed up to 100 months

  4. Duration of Response

    From the time of first response to disease progression or death from any cause, whichever came first, assessed up to 100 months

    Time frame: From the time of first response to disease progression or death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 12 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 15, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07530094
Lead sponsor
Ning Jiang, M.D./Ph.D.
Responsible party
Ning Jiang, M.D./Ph.D. (Jiangsu Cancer Institute & Hospital, Jiangsu Cancer Institute & Hospital) — Sponsor-investigator
First posted
Apr 15, 2026
Start date
Dec 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Xiangzhi Zhu
Contact
13182948068@163.com
+86 25 83283535
Ning Jiang
Contact
njiang117@njmu.edu.cn
+86 25 83283535
Xiangzhi Zhu
study director · Jiangsu Cancer Institute & Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion